1.Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E et al: The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med 2017.
2.Meehan CJ, Moris P, Kohl TA, Pecerska J, Akter S, Merker M, Utpatel C, Beckert P, Gehre F, Lempens P et al: The relationship between transmission time and clustering methods in Mycobacterium tuberculosis epidemiology. EBioMedicine 2018, 37:410–416.
3.Tulu B, Ameni G: Spoligotyping based genetic diversity of Mycobacterium tuberculosis in Ethiopia: a systematic review. BMC Infect Dis 2018, 18(1):140.
4.Gagneux S, DeRiemer K, Van T, Kato-Maeda M, de Jong BC, Narayanan S, Nicol M, Niemann S, Kremer K, Gutierrez MC et al: Variable host-pathogen compatibility in Mycobacterium tuberculosis. ProcNatlAcadSciUSA 2006, 103(8):2869–2873.
5.Hershberg R, Lipatov M, Small PM, Sheffer H, Niemann S, Homolka S, Roach JC, Kremer K, Petrov DA, Feldman MW et al: High functional diversity in Mycobacterium tuberculosis driven by genetic drift and human demography. PLoS Biol 2008, 6(12):e311.
6.Wirth T, Hildebrand F, Allix-Beguec C, Wolbeling F, Kubica T, Kremer K, van Soolingen D, Rusch-Gerdes S, Locht C, Brisse S et al: Origin, spread and demography of the Mycobacterium tuberculosis complex. PLoS Pathog 2008, 4(9):e1000160.
7.Allix-Beguec C, Harmsen D, Weniger T, Supply P, Niemann S: Evaluation and strategy for use of MIRU-VNTRplus, a multifunctional database for online analysis of genotyping data and phylogenetic identification of Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2008, 46(8):2692–2699.
8.Juma SP, Maro A, Pholwat S, Mpagama SG, Gratz J, Liyoyo A, Houpt ER, Kibiki GS, Mmbaga BT, Heysell SK: Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania. BMC Infect Dis 2019, 19(1):129.
9.Magombedze G, Garira W, Mwenje E: Modelling the human immune response mechanisms to mycobacterium tuberculosis infection in the lungs. Math Biosci Eng 2006, 3(4):661–682.
10.Pasipanodya JG, Moonan PK, Vecino E, Miller TL, Fernandez M, Slocum P, Drewyer G, Weis SE: Allopatric tuberculosis host-pathogen relationships are associated with greater pulmonary impairment. Infect Genet Evol 2013, 16:433–440.
11.Shaw JE, Pasipanodya JG, Gumbo T: Meningeal tuberculosis: high long-term mortality despite standard therapy. Medicine (Baltimore) 2010, 89(3):189–195.
12.Pusch T, Pasipanodya JG, Hall RG, 2nd, Gumbo T: Therapy duration and long-term outcomes in extra-pulmonary tuberculosis. BMC Infect Dis 2014, 14:115.
13.Nanoo A, Izu A, Ismail NA, Ihekweazu C, Abubakar I, Mametja D, Madhi SA: Nationwide and regional incidence of microbiologically confirmed pulmonary tuberculosis in South Africa, 2004–12: a time series analysis. Lancet Infect Dis 2015, 15(9):1066–1076.
14.Hoogendoorn JC, Ranoto L, Muditambi N, Railton J, Maswanganyi M, Struthers HE, McIntyre JA, Peters RPH: Reduction in extrapulmonary tuberculosis in context of antiretroviral therapy scale-up in rural South Africa. Epidemiol Infect 2017, 145(12):2500–2509.
15.Marais BJ, Graham SM, Maeurer M, Zumla A: Progress and challenges in childhood tuberculosis. Lancet Infect Dis 2013, 13(4):287–289.
16.Pasipanodya JG, Nuermberger E, Romero K, Hanna D, Gumbo T: Systematic analysis of hollow fiber model of tuberculosis experiments. Clin Infect Dis 2015, 61 Suppl 1:S10–17.
17.Swaminathan S, Pasipanodya JG, Ramachandran G, Hemanth Kumar AK, Srivastava S, Deshpande D, Nuermberger E, Gumbo T: Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests. Clin Infect Dis 2016, 63(suppl 3):S63-S74.
18.Pasipanodya JG, Smythe W, Merle CS, Olliaro PL, Deshpande D, Magombedze G, McIlleron H, Gumbo T: Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis. Clin Infect Dis 2018, 67(suppl_3):S284-S292.
19.Beki T. Magazi SK, Robert Badal, Tawanda Gumbo, Jotam G. Pasipanodya: AI Molecular Characterization and Prediction in Carbapenem Resistant Enterobactericiacaecae from Intra-abdominal Infections in the SMART Study. Jornal of Antimicrobial and Chemotherapy 2018, In Review.
20.Pasipanodya JG, Gumbo T: A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs. Curr Opin Pharmacol 2011, 11(5):457–463.
21.Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T: Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011, 204(12):1951–1959.
22.Said HM, Kock MM, Ismail NA, Mphahlele M, Baba K, Omar SV, Osman AG, Hoosen AA, Ehlers MM: Molecular characterization and second-line antituberculosis drug resistance patterns of multidrug-resistant Mycobacterium tuberculosis isolates from the northern region of South Africa. J Clin Microbiol 2012, 50(9):2857–2862.
23.Streicher EM, Muller B, Chihota V, Mlambo C, Tait M, Pillay M, Trollip A, Hoek KG, Sirgel FA, Gey van Pittius NC et al: Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa. Infect Genet Evol 2012, 12(4):686–694.
24.Stavrum R, Mphahlele M, Ovreas K, Muthivhi T, Fourie PB, Weyer K, Grewal HM: High diversity of Mycobacterium tuberculosis genotypes in South Africa and preponderance of mixed infections among ST53 isolates. J Clin Microbiol 2009, 47(6):1848–1856.
25.Maningi NE, Daum LT, Rodriguez JD, Said HM, Peters RPH, Sekyere JO, Fischer GW, Chambers JP, Fourie PB: Multi- and Extensively Drug Resistant Mycobacterium tuberculosis in South Africa: a Molecular Analysis of Historical Isolates. J Clin Microbiol 2018, 56(5).
26.Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M et al: Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 1997, 35(4):907–914.
27.Couvin D, David A, Zozio T, Rastogi N: Macro-geographical specificities of the prevailing tuberculosis epidemic as seen through SITVIT2, an updated version of the Mycobacterium tuberculosis genotyping database. Infect Genet Evol 2018.
28.Breiman L, Friedman J, Stone CJ, Olshen RA: Classification and Regression Trees. Boca Raton: Chapman and Hall/CRC; 1984.
29.Breiman L: Statistical Modeling: The Two Cultures (with comments and a rejoinder by the author). Statistical Science 2001, 16(3):199–231.
30.Friedman JH: Multivariate adaptive regression splines. AnnStatist 1991, 19(1):1–68.
31.Friedman JH: Stochastic gradient boosting. In. Stanford University: Department of Statistics; 1999.
32.Friedman J, Popescu, BE: Predictive learning via rule ensembles. Ann Appl Stat 2008, 2(3):916–954.
33.Breiman L: Convergence Properties of a Learning Algorithm. The Annals of Mathematical Statistics 1964, 35(4):1819–1822.
34.Pasipanodya J, Gumbo T: An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob Agents Chemother 2011, 55(1):24–34.
35.Gumbo T, Pasipanodya JG, Romero K, Hanna D, Nuermberger E: Forecasting accuracy of the hollow fiber model of tuberculosis for clinical therapeutic outcomes. Clin Infect Dis 2015, 61 Suppl 1:S25–31.
36.Newcombe RG: Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998, 17(8):873–890.
37.Kulchavenya E: Extrapulmonary tuberculosis: are statistical reports accurate? Ther Adv Infect Dis 2014, 2(2):61–70.
38.Caws M, Drobniewski FA: Molecular techniques in the diagnosis of Mycobacterium tuberculosis and the detection of drug resistance. AnnNYAcadSci 2001, 953:138–145.
39.Thwaites G, Caws M, Chau TT, D’Sa A, Lan NT, Huyen MN, Gagneux S, Anh PT, Tho DQ, Torok E et al: Relationship between Mycobacterium tuberculosis genotype and the clinical phenotype of pulmonary and meningeal tuberculosis. J ClinMicrobiol 2008, 46(4):1363–1368.
40.Thwaites GE, Chau TT, Caws M, Phu NH, Chuong LV, Sinh DX, Drobniewski F, White NJ, Parry CM, Farrar JJ: Isoniazid resistance, mycobacterial genotype and outcome in Vietnamese adults with tuberculous meningitis. IntJ TubercLung Dis 2002, 6(10):865–871.
41.Vinnard C, Winston CA, Wileyto EP, MacGregor RR, Bisson GP: Multidrug resistant tuberculous meningitis in the United States, 1993–2005. J Infect 2011, 63(3):240–242.
42.Vinnard C, Winston CA, Wileyto EP, MacGregor RR, Bisson GP: Isoniazid-resistant tuberculous meningitis, United States, 1993–2005. Emerg Infect Dis 2011, 17(3):539–542.
43.Dheda K, Lenders L, Magombedze G, Srivastava S, Raj P, Arning E, Ashcraft P, Bottiglieri T, Wainwright H, Pennel T et al: Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis. Am J Respir Crit Care Med 2018, 198(9):1208–1219.
44.Edginton ME, Wong ML, Phofa R, Mahlaba D, Hodkinson HJ: Tuberculosis at Chris Hani Baragwanath Hospital: numbers of patients diagnosed and outcomes of referrals to district clinics. Int J Tuberc Lung Dis 2005, 9(4):398–402.
45.Karstaedt AS: Extrapulmonary tuberculosis among adults: experience at Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa. S Afr Med J 2013, 104(1):22–24.
46.Maguga-Phasha NTC, Munyai NS, Mashinya F, Makgatho ME, Mbajiorgu EF: Genetic diversity and distribution of Mycobacterium tuberculosis genotypes in Limpopo, South Africa. BMC Infect Dis 2017, 17(1):764.
47.Nicol MP, Sola C, February B, Rastogi N, Steyn L, Wilkinson RJ: Distribution of strain families of Mycobacterium tuberculosis causing pulmonary and extrapulmonary disease in hospitalized children in Cape Town, South Africa. J ClinMicrobiol 2005, 43(11):5779–5781.
48.Middelkoop K, Bekker LG, Mathema B, Shashkina E, Kurepina N, Whitelaw A, Fallows D, Morrow C, Kreiswirth B, Kaplan G et al: Molecular epidemiology of Mycobacterium tuberculosis in a South African community with high HIV prevalence. J Infect Dis 2009, 200(8):1207–1211.
49.Srivastava S, Musuka S, Sherman C, Meek C, Leff R, Gumbo T: Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis 2010, 201(8):1225–1231.
50.Schmalstieg AM, Srivastava S, Belkaya S, Deshpande D, Meek C, Leff R, van Oers NS, Gumbo T: The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. Antimicrob Agents Chemother 2012, 56(9):4806–4815.
51.Pasipanodya JG, Srivastava S, Gumbo T: Acquired drug resistance because of pharmacokinetic variability in a young child with tuberculosis. Pediatr Infect Dis J 2014, 33(11):1205.
52.World Health O: Treatment of tuberculosis: Guidelines. Fourth edition. In., vol. WHO/HTM/TB/2009.420. Geneva: World Health Organization; 2010.
53.Kranzer K, Afnan-Holmes H, Tomlin K, Golub JE, Shapiro AE, Schaap A, Corbett EL, Lonnroth K, Glynn JR: The benefits to communities and individuals of screening for active tuberculosis disease: a systematic review. Int J Tuberc Lung Dis 2013, 17(4):432–446.
54.Peto HM, Pratt RH, Harrington TA, LoBue PA, Armstrong LR: Epidemiology of extrapulmonary tuberculosis in the United States, 1993–2006. Clin Infect Dis 2009, 49(9):1350–1357.